Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

NCT07664839 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
NPM1 Mutation
IDH1 Mutation
IDH2 Mutation

Interventions

DRUG: VEN combined with azacitidine
DRUG: Cytarabine plus Daunorubicin

Sponsor

Shen yang